Millennium Pharmaceuticals, Inc. v. Sandoz Inc.
862 F.3d 1356
Fed. Cir.2017Background
- Millennium owns U.S. Patent No. 6,713,446 claiming a lyophilized D‑mannitol ester of bortezomib (Velcade®), a prodrug that improved stability, solubility, and clinical utility of bortezomib for cancer treatment.
- Bortezomib (the Adams patent) and its clinical activity were known, but prior formulations suffered instability, rapid degradation, and insolubility; many prior formulation attempts failed.
- Inventors discovered that lyophilizing bortezomib with mannitol produced a previously unknown D‑mannitol boronate ester that solved these formulation problems and enabled FDA approval of Velcade®.
- Sandoz (and later Apotex and Teva) filed ANDAs admitting infringement but arguing the asserted claims (20, 31, 49, 53) were invalid as obvious; the district court agreed and held the claims invalid.
- The Federal Circuit reversed the district court for the Sandoz cases, finding Sandoz failed to prove obviousness by clear and convincing evidence, and vacated/remanded the Apotex/Teva judgments so they may relitigate.
Issues
| Issue | Plaintiff's Argument (Millennium) | Defendant's Argument (Sandoz/Apotex/Teva) | Held |
|---|---|---|---|
| Obviousness of claimed D‑mannitol ester | Prior art did not teach or suggest making the mannitol ester; invention solved long‑felt problems and produced unexpected results | Lyophilization and use of mannitol were known; ester formation was the "natural result" (inherent) of lyophilizing with mannitol | Reversed: defendants failed to show motivation or reasonable expectation to form this specific ester; not obvious under §103 |
| Inherency (product formed by known process) | Inventor’s path is irrelevant; prior art must show inherency to the person of ordinary skill, which it did not | Lyophilization with mannitol inevitably produces the ester, so product is inherent | Rejected: high standard for inherency not met; no evidence that ester formation was necessarily present or predictable |
| Objective indicia (unexpected results, long‑felt need) | Velcade® demonstrated unexpected improved stability/solubility/dissociation vs. bortezomib; long‑felt unmet need and prior failures support nonobviousness | District court erred to require comparison to an unmade glycerol ester or to attribute success solely to bortezomib | Accepted: objective indicia were strong and improperly discounted; they rebut obviousness |
| Collateral estoppel / effect on Apotex & Teva cases | If Sandoz judgment reversed, Apotex/Teva dismissals based on collateral estoppel should be vacated so they can present defenses | Stipulated earlier to collateral estoppel based on district court judgment | Court vacated and remanded Apotex/Teva judgments for further proceedings in light of reversal |
Key Cases Cited
- Graham v. John Deere Co., 383 U.S. 1 (sets factual/legal framework for obviousness analysis)
- KSR Int’l Co. v. Teleflex Inc., 550 U.S. 398 (reason‑to‑combine/obviousness inquiry guidance)
- Microsoft Corp. v. i4i Ltd. P'ship, 564 U.S. 91 (clear‑and‑convincing standard for invalidity of issued patents)
- In re Cyclobenzaprine Hydrochloride Extended‑Release Capsule Patent Litig., 676 F.3d 1063 (importance of considering objective indicia)
- Otsuka Pharm. Co. v. Sandoz, Inc., 678 F.3d 1280 (motivation to modify lead compound standard)
- Par Pharm., Inc. v. TWI Pharm., Inc., 773 F.3d 1186 (standards on inherency and obviousness)
- Pfizer, Inc. v. Apotex, Inc., 480 F.3d 1348 (burden to show motivation and reasonable expectation of success)